-
1
-
-
0033533853
-
Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2, 1-c][1,4]benzodiazepine system
-
Wilson SC, Howard PW, Forrow SM et al. Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2, 1-c][1,4]benzodiazepine system. J Med Chem 1999; 42: 4028-4041.
-
(1999)
J Med Chem
, vol.42
, pp. 4028-4041
-
-
Wilson, S.C.1
Howard, P.W.2
Forrow, S.M.3
-
2
-
-
0031017942
-
Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4] benzodiazepines
-
Puwada MS, Forrow SA, Hartley JA et al. Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4] benzodiazepines. Biochemistry 1997; 36: 2478-2484.
-
(1997)
Biochemistry
, vol.36
, pp. 2478-2484
-
-
Puwada, M.S.1
Forrow, S.A.2
Hartley, J.A.3
-
3
-
-
0027178818
-
A quantitative assay to measure the relative DNA-binding affinity of pyrrolo[2,1-c] [1,4]benzodiazepine (PBD) antitumor antibiotics based on the inhibition of restriction endonuclease BamHI
-
Puwada MS, Hartley JA, Jenkins TC et al. A quantitative assay to measure the relative DNA-binding affinity of pyrrolo[2,1-c] [1,4]benzodiazepine (PBD) antitumor antibiotics based on the inhibition of restriction endonuclease BamHI. Nucleic Acids Res 1993; 21: 3671-3675.
-
(1993)
Nucleic Acids Res
, vol.21
, pp. 3671-3675
-
-
Puwada, M.S.1
Hartley, J.A.2
Jenkins, T.C.3
-
4
-
-
0018833348
-
Antitumor effect of a new antibiotic, neothramycin
-
Hisamatsu T, Uchida S, Tackeuchi T et al. Antitumor effect of a new antibiotic, neothramycin. Gann 1980; 71: 308-312.
-
(1980)
Gann
, vol.71
, pp. 308-312
-
-
Hisamatsu, T.1
Uchida, S.2
Tackeuchi, T.3
-
5
-
-
0020132315
-
Phase I study of a new antitumor antibiotic, neothramycin
-
Kimura K, Ogawa M, Wakui A et al. Phase I study of a new antitumor antibiotic, neothramycin. Gan To Kagaku Ryoho 1982; 9: 924-929.
-
(1982)
Gan To Kagaku Ryoho
, vol.9
, pp. 924-929
-
-
Kimura, K.1
Ogawa, M.2
Wakui, A.3
-
6
-
-
0022970672
-
The treatment of bladder cancer by neothramycin
-
Tsugaya M, Washida H, Hirao N et al. The treatment of bladder cancer by neothramycin. Hinyokika Kiyo 1986; 32: 1443-1448.
-
(1986)
Hinyokika Kiyo
, vol.32
, pp. 1443-1448
-
-
Tsugaya, M.1
Washida, H.2
Hirao, N.3
-
7
-
-
0033736169
-
2,1-c)[1,4]benzodiazepine (PBD)-distamycin hybrid inhibits DNA binding to transcription factor Sp1
-
Baraldi PG, Cacciari B, Guiotto A et al. [2,1-c)[1,4]benzodiazepine (PBD)-distamycin hybrid inhibits DNA binding to transcription factor Sp1. Nucleosides Nucleotides Nucleic Acids 2000; 19: 1219-1229.
-
(2000)
Nucleosides Nucleotides Nucleic Acids
, vol.19
, pp. 1219-1229
-
-
Baraldi, P.G.1
Cacciari, B.2
Guiotto, A.3
-
8
-
-
0034929708
-
Sp1 and Krueppel-like factor family of transcription factors in cell growth regulation and cancer
-
Black A, Black JD, Azizkhan-Clifford J. Sp1 and Krueppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001; 188: 143-160.
-
(2001)
J Cell Physiol
, vol.188
, pp. 143-160
-
-
Black, A.1
Black, J.D.2
Azizkhan-Clifford, J.3
-
9
-
-
0037489428
-
Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: Kinetic and molecular modeling studies with pyrrolobenzodiazepine dimmers
-
Smellie M., Bose DS, Thompson AS, et al. Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: kinetic and molecular modeling studies with pyrrolobenzodiazepine dimmers. Biochemistry 2003; 42: 8232-8239.
-
(2003)
Biochemistry
, vol.42
, pp. 8232-8239
-
-
Smellie, M.1
Bose, D.S.2
Thompson, A.S.3
-
10
-
-
3543044968
-
Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent
-
Wilkinson GP, Taylor JP, Shnyder S et al. Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent. Invest New Drugs 2004; 22: 231-240.
-
(2004)
Invest New Drugs
, vol.22
, pp. 231-240
-
-
Wilkinson, G.P.1
Taylor, J.P.2
Shnyder, S.3
|